🇺🇸 FDA
Patent

US 10421802

Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides

granted A61KA61K39/42A61K45/06

Quick answer

US patent 10421802 (Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K39/42, A61K45/06